NRAS and melanoma: Targeting both the RAS-effector arms, either by combined BRAF and PIK3CA or MEK1+2 and PIK3CA together, effectively delayed the tumor growth (Figure 5D and 5E) confirming the importance of both the PI3K and RAF effector arms in the IPC298 NRAS-mutant melanoma line for tumor growth.